Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial

Show simple item record

dc.contributor.author Guwatudde, D.
dc.contributor.author Ezeamama, A.E.
dc.contributor.author Bagenda, D.
dc.contributor.author Kyeyune, R.
dc.contributor.author Wabwire-Mangen, F.
dc.contributor.author Wamani, H.
dc.contributor.author Mugusi, F.
dc.contributor.author Spiegelman, D.
dc.contributor.author Wang, M.
dc.contributor.author Manabe, Y.C.
dc.contributor.author Fawzi, W.W.
dc.date.accessioned 2013-04-18T10:24:33Z
dc.date.available 2013-04-18T10:24:33Z
dc.date.issued 2012
dc.identifier.citation Guwatudde, D., Ezeamama, A. E., Bagenda, D., Kyeyune, R., Wabwire-Mangen, F., Wamani, H., ... & Fawzi, W. W. (2012). Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC infectious diseases, 12(1), 304.
dc.identifier.issn 1471-2334/12/304
dc.identifier.other doi: 10.1186/1471-2334-12-304.
dc.identifier.uri http://hdl.handle.net/123456789/864
dc.description.abstract BACKGROUND: Use of multivitamin supplements during the pre-HAART era has been found to reduce viral load, enhance immune response, and generally improve clinical outcomes among HIV-infected adults. However, immune reconstitution is incomplete and significant mortality and opportunistic infections occur in spite of HAART. There is insufficient research information on whether multivitamin supplementation may be beneficial as adjunct therapy for HIV-infected individuals taking HAART. We propose to evaluate the efficacy of a single recommended daily allowance (RDA) of micronutrients (including vitamins B-complex, C, and E) in slowing disease progression among HIV-infected adults receiving HAART in Uganda. METHODS/DESIGN: We are using a randomized, double-blind, placebo-controlled trial study design. Eligible patients are HIV-positive adults aged at least 18 years, and are randomized to receive either a placebo; or multivitamins that include a single RDA of the following vitamins: 1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 2.6 mcg B12, 18 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid. Participants are followed for up to 18 months with evaluations at baseline, 6, 12 and 18 months. The study is primarily powered to examine the effects on immune reconstitution, weight gain, and quality of life. In addition, we will examine the effects on other secondary outcomes including the risks of development of new or recurrent disease progression event, including all-cause mortality; ARV regimen change from first- to second-line therapy; and other adverse events as indicated by incident peripheral neuropathy, severe anemia, or diarrhea. DISCUSSIONS: The conduct of this trial provides an opportunity to evaluate the potential benefits of this affordable adjunct therapy (multivitamin supplementation) among HIV-infected adults receiving HAART in a developing country setting. en_GB
dc.language.iso en en_GB
dc.publisher BMC Infectious Diseases
dc.relation.ispartofseries BMC Infectious Diseases ;12:304
dc.subject HIV infected adults en_GB
dc.subject HAART en_GB
dc.subject Micronutrient supplementation en_GB
dc.subject Nutrition en_GB
dc.subject Randomized double-blind placebocontrolled trial en_GB
dc.subject Trial protocol
dc.subject Uganda
dc.subject Sub-Saharan Africa
dc.title Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial en_GB
dc.type Article en_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MUHAS IR


Advanced Search

Browse

My Account